THIORIDAZINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Thioridazine Hydrochloride, and when can generic versions of Thioridazine Hydrochloride launch?
Thioridazine Hydrochloride is a drug marketed by Actavis Mid Atlantic, Alpharma Us Pharms, Ani Pharms, Epic Pharma Llc, Pharm Assoc, Sandoz, Wockhardt, Chartwell Rx, Heritage Pharma Avet, Mutual Pharm, Mylan, Par Pharm, Roxane, Sun Pharm Industries, Superpharm, Watson Labs, Watson Labs Teva, and West Ward. and is included in seventy-nine NDAs.
The generic ingredient in THIORIDAZINE HYDROCHLORIDE is thioridazine hydrochloride. There are eighteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the thioridazine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thioridazine Hydrochloride
A generic version of THIORIDAZINE HYDROCHLORIDE was approved as thioridazine hydrochloride by MYLAN on March 15th, 1983.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for THIORIDAZINE HYDROCHLORIDE?
- What are the global sales for THIORIDAZINE HYDROCHLORIDE?
- What is Average Wholesale Price for THIORIDAZINE HYDROCHLORIDE?
Summary for THIORIDAZINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 18 |
NDAs: | 79 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Clinical Trials: | 10 |
Patent Applications: | 3,180 |
DailyMed Link: | THIORIDAZINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for THIORIDAZINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rambam Health Care Campus | Early Phase 1 |
Rabin Medical Center | Early Phase 1 |
State University of New York at Buffalo | Phase 4 |
Pharmacology for THIORIDAZINE HYDROCHLORIDE
Drug Class | Phenothiazine |